{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:27:58Z","timestamp":1786969678554,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Evidence-based treatments to improve renal outcomes in patients with advanced chronic kidney disease (CKD) after acute myocardial infarction (AMI) are limited. We aimed to evaluate the clinical effects of colchicine therapy after AMI in these patients. This retrospective cohort study used data from the TriNetX US Collaborative Network and included adults with an estimated glomerular filtration rate\u2009\u2264\u200945\u00a0mL\/min\/1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    who were newly diagnosed with AMI between January 1, 2012, and December 31, 2022. Patients were grouped by colchicine use within 1\u00a0month after AMI and matched 1:1 by propensity score (n\u2009=\u20091,200 per group). Cox proportional-hazards and Kaplan\u2013Meier analyses assessed outcomes. The primary outcome was dialysis dependence; secondary outcomes included major adverse cardiac events (MACE) and mortality. A landmark analysis was conducted for different colchicine initiation times after AMI. Over a maximum follow-up period of 4\u00a0years, colchicine use within one month was associated with reduced risks of dialysis dependence (hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.53\u20130.79) compared to non-use. However, no significant between-group difference was observed in the risk of MACE (HR 1.04; 95% CI 0.94\u20131.15) and all-cause mortality (HR 1.03; 95% CI 0.87\u20131.22). These results were consistent in the landmark analysis. Notably, initiation of colchicine within two weeks was associated with a lower risk of all-cause mortality (HR 0.85; 95% CI 0.73\u20130.99) in landmark analyses. In patients with advanced CKD experiencing AMI, early colchicine therapy may reduce the risks of dialysis dependence. Any potential survival benefit remains uncertain and should be confirmed in prospective studies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-54682-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:15:13Z","timestamp":1780596913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Colchicine use after acute myocardial infarction is associated with reduced dialysis dependence in advanced chronic kidney disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Cheng-Chun","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsiang","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"5","key":"54682_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96(5), 1048\u20131050. https:\/\/doi.org\/10.1016\/j.kint.2019.07.012 (2019).","journal-title":"Kidney Int."},{"key":"54682_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","volume":"2","author":"N Bansal","year":"2017","unstructured":"Bansal, N. et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: An analysis of 3 community-based cohort studies. JAMA Cardiol. 2, 314\u2013318. https:\/\/doi.org\/10.1001\/jamacardio.2016.4652 (2017).","journal-title":"JAMA Cardiol."},{"key":"54682_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03084-3","volume":"23","author":"C Engelbertz","year":"2023","unstructured":"Engelbertz, C. et al. Contemporary in-hospital and long-term prognosis of patients with acute ST-elevation myocardial infarction depending on renal function: A retrospective analysis. BMC Cardiovasc. Disord. 23, 62. https:\/\/doi.org\/10.1186\/s12872-023-03084-3 (2023).","journal-title":"BMC Cardiovasc. Disord."},{"key":"54682_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02573-1","volume":"22","author":"J Schmucker","year":"2022","unstructured":"Schmucker, J. et al. Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: Results from the Bremen STEMI registry. BMC Cardiovasc. Disord. 22, 142. https:\/\/doi.org\/10.1186\/s12872-022-02573-1 (2022).","journal-title":"BMC Cardiovasc. Disord."},{"key":"54682_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000542628","volume":"15","author":"C Zoccali","year":"2025","unstructured":"Zoccali, C. A new clinical entity bridging the cardiovascular system and the kidney: The chronic cardiovascular-kidney disorder. Cardiorenal Med. 15, 21\u201328. https:\/\/doi.org\/10.1159\/000542628 (2025).","journal-title":"Cardiorenal Med."},{"key":"54682_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.11909\/j.issn.1671-5411.2015.03.020","volume":"12","author":"L Fang","year":"2015","unstructured":"Fang, L., Moore, X. L., Dart, A. M. & Wang, L. M. Systemic inflammatory response following acute myocardial infarction. J. Geriatr. Cardiol. 12, 305\u2013312. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2015.03.020 (2015).","journal-title":"J. Geriatr. Cardiol."},{"key":"54682_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.032671","volume":"13","author":"N Weight","year":"2024","unstructured":"Weight, N. et al. Impact of chronic kidney disease on the processes of care and long-term mortality of non-ST-segment-elevation myocardial infarction: A nationwide cohort study and long-term follow-up. J. Am. Heart Assoc. 13, e032671. https:\/\/doi.org\/10.1161\/jaha.123.032671 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"54682_CR8","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/ckj\/sfad135","volume":"16","author":"T Sarakpi","year":"2023","unstructured":"Sarakpi, T., Mesic, A. & Speer, T. Leukocyte-endothelial interaction in CKD. Clin. Kidney J. 16, 1845\u20131860. https:\/\/doi.org\/10.1093\/ckj\/sfad135 (2023).","journal-title":"Clin. Kidney J."},{"key":"54682_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.kint.2022.10.030","volume":"103","author":"S Rayego-Mateos","year":"2023","unstructured":"Rayego-Mateos, S. et al. Targeting inflammation to treat diabetic kidney disease: The road to 2030. Kidney Int. 103, 282\u2013296. https:\/\/doi.org\/10.1016\/j.kint.2022.10.030 (2023).","journal-title":"Kidney Int."},{"key":"54682_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/eurheartj\/ehae933","volume":"46","author":"L Saba","year":"2025","unstructured":"Saba, L. et al. Carotid artery atherosclerosis: Mechanisms of instability and clinical implications. Eur. Heart J. 46, 904\u2013921. https:\/\/doi.org\/10.1093\/eurheartj\/ehae933 (2025).","journal-title":"Eur. Heart J."},{"key":"54682_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.iccl.2023.06.006","volume":"12","author":"A Mehta","year":"2023","unstructured":"Mehta, A., Chandiramani, R., Spirito, A., Vogel, B. & Mehran, R. Significance of kidney disease in cardiovascular disease patients. Interv. Cardiol. Clin. 12, 453\u2013467. https:\/\/doi.org\/10.1016\/j.iccl.2023.06.006 (2023).","journal-title":"Interv. Cardiol. Clin."},{"key":"54682_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","author":"N Kelley","year":"2019","unstructured":"Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20133328 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"54682_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2023.0067","volume":"47","author":"SH Suh","year":"2023","unstructured":"Suh, S. H. & Kim, S. W. Dyslipidemia in patients with chronic kidney disease: An updated overview. Diabetes Metab. J. 47, 612\u2013629. https:\/\/doi.org\/10.4093\/dmj.2023.0067 (2023).","journal-title":"Diabetes Metab. J."},{"key":"54682_CR14","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1912388 (2019).","journal-title":"N. Engl. J. Med."},{"key":"54682_CR15","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838\u20131847. https:\/\/doi.org\/10.1056\/NEJMoa2021372 (2020).","journal-title":"N. Engl. J. Med."},{"key":"54682_CR16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/heartjnl-2023-323177","volume":"110","author":"B Tucker","year":"2024","unstructured":"Tucker, B., Goonetilleke, N., Patel, S. & Keech, A. Colchicine in atherosclerotic cardiovascular disease. Heart 110, 618\u2013625. https:\/\/doi.org\/10.1136\/heartjnl-2023-323177 (2024).","journal-title":"Heart"},{"key":"54682_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103453","volume":"155","author":"YJ Lee","year":"2025","unstructured":"Lee, Y. J. et al. Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study. J. Autoimmun. 155, 103453. https:\/\/doi.org\/10.1016\/j.jaut.2025.103453 (2025).","journal-title":"J. Autoimmun."},{"key":"54682_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf048","author":"YH Chen","year":"2025","unstructured":"Chen, Y. H., Fang, Y. W., Chen, M. T., Liou, H. H. & Tsai, M. H. Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: A retrospective study. Eur. Heart J. Cardiovasc. Pharmacother. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf048 (2025).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"54682_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54171-8","volume":"15","author":"JY Sheu","year":"2024","unstructured":"Sheu, J. Y. et al. The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients. Nat. Commun. 15, 10043. https:\/\/doi.org\/10.1038\/s41467-024-54171-8 (2024).","journal-title":"Nat. Commun."},{"key":"54682_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s44200-021-00006-6","volume":"27","author":"JM Cherubini","year":"2021","unstructured":"Cherubini, J. M. & MacDonald, M. J. Statistical inferences using effect sizes in human endothelial function research. Artery Res. 27, 176\u2013185. https:\/\/doi.org\/10.1007\/s44200-021-00006-6 (2021).","journal-title":"Artery Res."},{"key":"54682_CR21","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z., Kim, H. J., Lonjon, G. & Zhu, Y. Balance diagnostics after propensity score matching. Ann. Transl. Med. 7, 16. https:\/\/doi.org\/10.21037\/atm.2018.12.10 (2019).","journal-title":"Ann. Transl. Med."},{"key":"54682_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jclinepi.2014.09.005","volume":"68","author":"JF Cohen","year":"2015","unstructured":"Cohen, J. F. et al. Cochran\u2019s Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy. J. Clin. Epidemiol. 68, 299\u2013306. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.09.005 (2015).","journal-title":"J. Clin. Epidemiol."},{"key":"54682_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176297","volume":"964","author":"J Hu","year":"2024","unstructured":"Hu, J. et al. Colchicine ameliorates short-term abdominal aortic aneurysms by inhibiting the expression of NLRP3 inflammasome components in mice. Eur. J. Pharmacol. 964, 176297. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176297 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"54682_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/ndt\/gfz073","volume":"35","author":"WH Hsu","year":"2020","unstructured":"Hsu, W. H. et al. Compound K inhibits priming and mitochondria-associated activating signals of NLRP3 inflammasome in renal tubulointerstitial lesions. Nephrol. Dial. Transplant. 35, 74\u201385. https:\/\/doi.org\/10.1093\/ndt\/gfz073 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"54682_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108053","volume":"236","author":"S Toldo","year":"2022","unstructured":"Toldo, S. et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol. Ther. 236, 108053. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108053 (2022).","journal-title":"Pharmacol. Ther."},{"key":"54682_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/fjc.0000000000000717","volume":"74","author":"AG Mauro","year":"2019","unstructured":"Mauro, A. G., Bonaventura, A., Mezzaroma, E., Quader, M. & Toldo, S. NLRP3 inflammasome in acute myocardial infarction. J. Cardiovasc. Pharmacol. 74, 175\u2013187. https:\/\/doi.org\/10.1097\/fjc.0000000000000717 (2019).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"54682_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.clinthera.2019.02.003","volume":"41","author":"C Khandkar","year":"2019","unstructured":"Khandkar, C., Vaidya, K. & Patel, S. Colchicine for stroke prevention: A systematic review and meta-analysis. Clin. Ther. 41, 582-590.e583. https:\/\/doi.org\/10.1016\/j.clinthera.2019.02.003 (2019).","journal-title":"Clin. Ther."},{"key":"54682_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.033450","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Inflammation and adverse outcomes in patients with acute ischemic stroke with and without chronic kidney disease. J. Am. Heart Assoc. 13, e033450. https:\/\/doi.org\/10.1161\/jaha.123.033450 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"54682_CR29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s11255-023-03516-1","volume":"55","author":"G Hawthorne","year":"2023","unstructured":"Hawthorne, G., Lightfoot, C. J., Smith, A. C., Khunti, K. & Wilkinson, T. J. Multimorbidity prevalence and patterns in chronic kidney disease: Findings from an observational multicentre UK cohort study. Int. Urol. Nephrol. 55, 2047\u20132057. https:\/\/doi.org\/10.1007\/s11255-023-03516-1 (2023).","journal-title":"Int. Urol. Nephrol."},{"key":"54682_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237149","author":"R Chermiti","year":"2024","unstructured":"Chermiti, R., Burtey, S. & Dou, L. Role of uremic toxins in vascular inflammation associated with chronic kidney disease. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm13237149 (2024).","journal-title":"J. Clin. Med."},{"key":"54682_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-008-1046-0","volume":"24","author":"DM Silverstein","year":"2009","unstructured":"Silverstein, D. M. Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr. Nephrol. 24, 1445\u20131452. https:\/\/doi.org\/10.1007\/s00467-008-1046-0 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"54682_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/ncpneph0954","volume":"4","author":"J Kendrick","year":"2008","unstructured":"Kendrick, J. & Chonchol, M. B. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat. Clin. Pract. Nephrol. 4, 672\u2013681. https:\/\/doi.org\/10.1038\/ncpneph0954 (2008).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"54682_CR33","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3892\/mmr.2017.6539","volume":"15","author":"S Itano","year":"2017","unstructured":"Itano, S. et al. Colchicine attenuates renal fibrosis in a murine unilateral ureteral obstruction model. Mol. Med. Rep. 15, 4169\u20134175. https:\/\/doi.org\/10.3892\/mmr.2017.6539 (2017).","journal-title":"Mol. Med. Rep."},{"key":"54682_CR34","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne, R. A. et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44, 3720\u20133826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191 (2023).","journal-title":"Eur Heart J"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54682-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:02:42Z","timestamp":1786968162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54682-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54682"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54682-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25626"}}